SARS-CoV-2 vaccines: a triumph of science and collaboration

Roughly 1 year after the first case of COVID-19 was identified and less than 1 year after the sequencing of SARS-CoV-2, multiple SARS-CoV-2 vaccines with demonstrated safety and efficacy in phase III clinical trials are available. The most promising vaccines have targeted the surface glycoprotein (S...

Descripción completa

Detalles Bibliográficos
Autores principales: Golob, Jonathan L., Lugogo, Njira, Lauring, Adam S., Lok, Anna S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262277/
https://www.ncbi.nlm.nih.gov/pubmed/33822773
http://dx.doi.org/10.1172/jci.insight.149187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262277/
https://www.ncbi.nlm.nih.gov/pubmed/33822773
http://dx.doi.org/10.1172/jci.insight.149187

Ejemplares similares